In vitro studies on various types of cancer have reported that sensitivity to TOP2A inhibitors depends on changes in the expression level of this gene, due to the fact that cells that are expressed at low levels show less sensitivity to drugs than those that are overexpressed [50]. This evidence concerns the gene TOP2A and cancer.